126
|
Abratenko P, An R, Anthony J, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Bathe-Peters L, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhat A, Bishai M, Blake A, Bolton T, Book JY, Camilleri L, Caratelli D, Caro Terrazas I, Castillo Fernandez R, Cavanna F, Cerati G, Chen Y, Cianci D, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Dennis SR, Devitt D, Diurba R, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Evans JJ, Fine R, Fiorentini Aguirre GA, Fitzpatrick RS, Fleming BT, Foppiani N, Franco D, Furmanski AP, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hall E, Hen O, Horton-Smith GA, Hourlier A, Itay R, James C, Ji X, Jiang L, Jo JH, Johnson RA, Jwa YJ, Kamp N, Kaneshige N, Karagiorgi G, Ketchum W, Kirby M, Kobilarcik T, Kreslo I, LaZur R, Lepetic I, Li K, Li Y, Lin K, Littlejohn BR, Louis WC, Luo X, Manivannan K, Mariani C, Marsden D, Marshall J, Martinez Caicedo DA, Mason K, Mastbaum A, McConkey N, Meddage V, Mettler T, Miller K, Mills J, Mistry K, Mogan A, Mohayai T, Moon J, Mooney M, Moor AF, Moore CD, Mora Lepin L, Mousseau J, Murphy M, Naples D, Navrer-Agasson A, Neely RK, Nowak J, Nunes M, Palamara O, Paolone V, Papadopoulou A, Papavassiliou V, Pate SF, Paudel A, Pavlovic Z, Piasetzky E, Ponce-Pinto ID, Prince S, Qian X, Raaf JL, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rice LCJ, Rochester L, Rodriguez Rondon J, Rogers HE, Rosenberg M, Ross-Lonergan M, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Shi J, Siegel H, Sinclair J, Smith A, Snider EL, Soderberg M, Söldner-Rembold S, Spentzouris P, Spitz J, Stancari M, John JS, Strauss T, Sutton K, Sword-Fehlberg S, Szelc AM, Tagg N, Tang W, Terao K, Thorpe C, Totani D, Toups M, Tsai YT, Uchida MA, Usher T, Van De Pontseele W, Viren B, Weber M, Wei H, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wresilo K, Wright N, Wu W, Yandel E, Yang T, Yarbrough G, Yates LE, Zeller GP, Zennamo J, Zhang C. Search for a Higgs Portal Scalar Decaying to Electron-Positron Pairs in the MicroBooNE Detector. PHYSICAL REVIEW LETTERS 2021; 127:151803. [PMID: 34678031 DOI: 10.1103/physrevlett.127.151803] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Revised: 08/11/2021] [Accepted: 09/10/2021] [Indexed: 06/13/2023]
Abstract
We present a search for the decays of a neutral scalar boson produced by kaons decaying at rest, in the context of the Higgs portal model, using the MicroBooNE detector. We analyze data triggered in time with the Fermilab NuMI neutrino beam spill, with an exposure of 1.93×10^{20} protons on target. We look for monoenergetic scalars that come from the direction of the NuMI hadron absorber, at a distance of 100 m from the detector, and decay to electron-positron pairs. We observe one candidate event, with a standard model background prediction of 1.9±0.8. We set an upper limit on the scalar-Higgs mixing angle of θ<(3.3-4.6)×10^{-4} at the 95% confidence level for scalar boson masses in the range (100-200) MeV/c^{2}. We exclude, at the 95% confidence level, the remaining model parameters required to explain the central value of a possible excess of K_{L}^{0}→π^{0}νν[over ¯] decays reported by the KOTO collaboration. We also provide a model-independent limit on a new boson X produced in K→πX decays and decaying to e^{+}e^{-}.
Collapse
|
127
|
Blakely C, Urisman A, Kerr D, Wu W, Bacaltos B, Rotow J, Gubens M, Jones K, Bivona T, Joo S, Riess J, Aisner D, Doebele R, Patil T, Schenk E, Kratz J, Jablons D. P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
128
|
Wu W, Wu C, Liu Y, Zhang Z, Liang Z. P59.02 Profile of Next-Generation Sequencing (NGS) on MET exon 14 Skipping Mutation and MET Amplification in Lung Cancer: A Calibration Project in China. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
129
|
Acciarri R, Adams C, Asaadi J, Baller B, Basque V, Cavanna F, de Gouvêa A, Fitzpatrick RS, Fleming B, Green P, James C, Kelly KJ, Lepetic I, Luo X, Palamara O, Scanavini G, Soderberg M, Spitz J, Szelc AM, Wu W, Yang T. New Constraints on Tau-Coupled Heavy Neutral Leptons with Masses m_{N}=280-970 MeV. PHYSICAL REVIEW LETTERS 2021; 127:121801. [PMID: 34597110 DOI: 10.1103/physrevlett.127.121801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 08/12/2021] [Indexed: 06/13/2023]
Abstract
A search for heavy neutral leptons has been performed with the ArgoNeuT detector exposed to the NuMI neutrino beam at Fermilab. We search for the decay signature N→νμ^{+}μ^{-}, considering decays occurring both inside ArgoNeuT and in the upstream cavern. In the data, corresponding to an exposure to 1.25×10^{20} POT, zero passing events are observed consistent with the expected background. This measurement leads to a new constraint at 90% confidence level on the mixing angle |U_{τN}|^{2} of tau-coupled Dirac heavy neutral leptons with masses m_{N}=280-970 MeV, assuming |U_{eN}|^{2}=|U_{μN}|^{2}=0.
Collapse
|
130
|
Hodgson D, Lai Z, Dearden S, Barrett JC, Harrington EA, Timms K, Lanchbury J, Wu W, Allen A, Senkus E, Domchek SM, Robson M. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. Ann Oncol 2021; 32:1582-1589. [PMID: 34500047 DOI: 10.1016/j.annonc.2021.08.2154] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 08/04/2021] [Accepted: 08/27/2021] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Presence of a germline BRCA1 and/or BRCA2 mutation (gBRCAm) may sensitize tumors to poly(ADP-ribose) polymerase (PARP) inhibition via inactivation of the second allele, resulting in gene-specific loss of heterozygosity (gsLOH) and homologous recombination deficiency (HRD). Here we explore whether tissue sample testing provides an additional route to germline testing to inform treatment selection for PARP inhibition. PATIENTS AND METHODS In this prespecified exploratory analysis, BRCA1 and/or BRCA2 mutations in blood samples (gBRCAm) and tumor tissue (tBRCAm) were analyzed from patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer and known gBRCAm, enrolled in the phase III OlympiAD trial. The frequency and nature of tBRCAm, HRD score status [HRD-positive (score ≥42) versus HRD-negative (score <42) using the Myriad myChoice® CDx test] and rates of gsLOH were determined, and their impact on clinical efficacy (objective response rate and progression-free survival) was explored. RESULTS Tissue samples from 161/302 patients yielded tBRCAm, HRD and gsLOH data for 143 (47%), 129 (43%) and 125 (41%) patients, respectively. Concordance between gBRCAm and tBRCAm was 99%. gsLOH was observed in 118/125 (94%) patients [BRCA1m, 73/76 (96%); BRCA2m, 45/49 (92%)]. A second mutation event was recorded for two of the three BRCA1m patients without gsLOH. The incidence of HRD-negative was 16% (21/129) and was more common for BRCA2m (versus BRCA1m) and/or for hormone receptor-positive (versus triple-negative) disease. Olaparib antitumor activity was observed irrespective of HRD score. CONCLUSIONS gBRCAm identified in patients with HER2-negative metastatic breast cancer by germline testing in blood was also identified by tumor tissue testing. gsLOH was common, indicating a high rate of biallelic inactivation in metastatic breast cancer. Olaparib activity was seen regardless of gsLOH status or HRD score. Thus, additional tumor testing to inform PARP inhibitor treatment selection may not be supported for these patients.
Collapse
|
131
|
Abratenko P, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Bathe-Peters L, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhat A, Bishai M, Blake A, Bolton T, Camilleri L, Caratelli D, Caro Terrazas I, Castillo Fernandez R, Cavanna F, Cerati G, Chen Y, Church E, Cianci D, Conrad J, Convery M, Cooper-Troendle L, Crespo-Anadón J, Del Tutto M, Dennis S, Devitt D, Diurba R, Domine L, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Escudero Sanchez L, Evans J, Fiorentini Aguirre G, Fitzpatrick R, Fleming B, Foppiani N, Franco D, Furmanski A, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hagaman L, Hall E, Hamilton P, Hen O, Hill C, Horton-Smith G, Hourlier A, Itay R, James C, Jan de Vries J, Ji X, Jiang L, Jo J, Johnson R, Jwa YJ, Kamp N, Kaneshige N, Karagiorgi G, Ketchum W, Kirby B, Kirby M, Kobilarcik T, Kreslo I, LaZur R, Lepetic I, Li K, Li Y, Littlejohn B, Lorca D, Louis W, Luo X, Marchionni A, Mariani C, Marsden D, Marshall J, Martin-Albo J, Martinez Caicedo D, Mason K, Mastbaum A, McConkey N, Meddage V, Mettler T, Miller K, Mills J, Mistry K, Mogan A, Mohayai T, Moon J, Mooney M, Moor A, Moore C, Mora Lepin L, Mousseau J, Murphy M, Naples D, Navrer-Agasson A, Neely R, Nienaber P, Nowak J, Palamara O, Paolone V, Papadopoulou A, Papavassiliou V, Pate S, Paudel A, Pavlovic Z, Piasetzky E, Ponce-Pinto I, Porzio D, Prince S, Qian X, Raaf J, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rochester L, Rodriguez Rondon J, Rogers H, Rosenberg M, Ross-Lonergan M, Russell B, Scanavini G, Schmitz D, Schukraft A, Seligman W, Shaevitz M, Sharankova R, Sinclair J, Smith A, Snider E, Soderberg M, Söldner-Rembold S, Soleti S, Spentzouris P, Spitz J, Stancari M, John J, Strauss T, Sutton K, Sword-Fehlberg S, Szelc A, Tagg N, Tang W, Terao K, Thorpe C, Toups M, Tsai YT, Uchida M, Usher T, Van De Pontseele W, Viren B, Weber M, Wei H, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wu W, Yandel E, Yang T, Yarbrough G, Yates L, Zeller G, Zennamo J, Zhang C. Measurement of the flux-averaged inclusive charged-current electron neutrino and antineutrino cross section on argon using the NuMI beam and the MicroBooNE detector. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.052002] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
132
|
King B, Kwon O, Mesinkovska N, Ko J, Dutronc Y, Wu W, McCollam J, Yu G, Holzwarth K, DeLozier A, Hordinsky M. LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1). J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.07.049] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
133
|
Wu W, Xuan Y, Ge Y, Mu S, Hu C, Fan R. Plasma miR-146a and miR-365 expression and inflammatory factors in patients with osteoarthritis. THE MALAYSIAN JOURNAL OF PATHOLOGY 2021; 43:311-317. [PMID: 34448795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
OBJECTIVE To investigate the expression levels of micro-ribonucleic acid (miR)-146a and miR-365 in the plasma of osteoarthritis (OA) patients, to study their expression with the inflammatory factors and the severity of disease in patients and to analyse their diagnostic significance. MATERIALS AND METHODS A total of 42 OA patients diagnosed with OA and treated in our hospital from January 2017 to January 2018 were selected as the subjects, and 28 healthy people were enrolled as controls. The expressions of interleukin-1 beta (IL-1β) and IL-6 in the plasma of OA patients were detected via immunohistochemical staining. Moreover, the knee joint function of OA patients was evaluated by Lysholm score, Western Ontario and McMaster Universities (WOMAC) score and Visual Analogue Scale (VAS) score. The expression levels of plasma miR-146a and miR-365 in OA patients were measured through RT-PCR. Besides, the significance of the expression levels of miR-146a and miR-365 for the diagnosis of OA was analysed by ROC curves. RESULTS As compared with healthy people, OA patients had elevated expression levels of plasma IL-1β and IL-6, decreased Lysholm score, increased WOMAC and VAS scores as well as significantly up-regulated levels of plasma miR-146a and miR-365, which were of important significance for diagnosis. CONCLUSION The expression levels of plasma miR-146a, miR-365 and inflammatory factors are notably higher, the disease is more severe, and the function of knee joint movement is weaker in OA patients than those in healthy controls. It can be concluded that the levels of both miR-146a and miR-365 can serve as biomarkers of OA diagnosis.
Collapse
|
134
|
Du XD, Hong RJ, Heidbrink WW, Jian X, Wang H, Eidietis NW, Van Zeeland MA, Austin ME, Liu Y, Crocker NA, Rhodes TL, Särkimäki K, Snicker A, Wu W, Knolker M. Multiscale Chirping Modes Driven by Thermal Ions in a Plasma with Reactor-Relevant Ion Temperature. PHYSICAL REVIEW LETTERS 2021; 127:025001. [PMID: 34296897 DOI: 10.1103/physrevlett.127.025001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 04/02/2021] [Accepted: 06/09/2021] [Indexed: 06/13/2023]
Abstract
A thermal ion driven bursting instability with rapid frequency chirping, considered as an Alfvénic ion temperature gradient mode, has been observed in plasmas having reactor-relevant temperature in the DIII-D tokamak. The modes are excited over a wide spatial range from macroscopic device size to microturbulence size and the perturbation energy propagates across multiple spatial scales. The radial mode structure is able to expand from local to global in ∼0.1 ms and it causes magnetic topology changes in the plasma edge, which can lead to a minor disruption event. Since the mode is typically observed in the high ion temperature ≳10 keV and high-β plasma regime, the manifestation of the mode in future reactors should be studied with development of mitigation strategies, if needed. This is the first observation of destabilization of the Alfvén continuum caused by the compressibility of ions with reactor-relevant ion temperature.
Collapse
|
135
|
Huang Y, Zhang LP, Hou LK, Dong ZW, Zhang W, Wu W, Wu CY. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2021; 50:773-778. [PMID: 34405613 DOI: 10.3760/cma.j.cn112151-20201224-00962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To pathologically evaluate the surgically resected specimens of three different therapies (neoadjuvant chemotherapy, neoadjuvant targeted therapy and neoadjuvant immunotherapy combined with chemotherapy) for non-small cell lung cancer. Methods: One-hundred and thirteen cases of post neoadjuvant therapy non-small cell lung cancer specimens were collected at Tongji University Affiliated Shanghai Pulmonary Hospital from January 2000 to March 2020. There were ninty patients receiving neoadjuvant chemotherapy (chemotherapy group;26 cases of adenocarcinoma and 64 cases of squamous cell carcinoma), 13 patients receiving neoadjuvant targeted therapy (targeted group;13 cases of adenocarcinoma) and 10 patients receiving neoadjuvant immunotherapy combined with chemotherapy (immune combined chemotherapy group;4 cases of adenocarcinoma and 6 cases of squamous cell carcinoma). They were evaluated for histologic tumor regression responses (necrosis, inflammatory cell infiltration, cholesterol crystal deposition, foam cell infiltration, reactive granuloma and interstitial collagenous formation) and pathological responses [main pathological response (MPR) and complete pathological response (PCR)]. Results: Chemotherapy group, targeted group and immune combined chemotherapy group all showed degenerative changes in residual tumor cells, increased atypia, various degrees of necrosis, foam cell aggregation, cholesterol cleft, inflammatory cell infiltration, and reactive granuloma in the tumor bed. Histologic characteristics of tumor regression reaction were not different between these three groups (P>0.05); the highest percentage of necrosis in the targeted group and immune combined chemotherapy group was only 10% and 20%, respectively, while that in the chemotherapy group was as high as 80%. One case of adenocarcinoma in immune combined chemotherapy group had tumor regression bed. The MPR rates of adenocarcinoma in chemotherapy group and squamous cell carcinoma in chemotherapy group were 35% (9/26) and 64% (41/64), respectively; the MPR ratio of targeted group was 2/13; the MPR ratio of adenocarcinomain immune combined chemotherapy group and squamous cell carcinoma in immune combined chemotherapy group were 2/4 and 2/6, respectively. The PCR rates of adenocarcinoma in chemotherapy group and squamous cell carcinoma in chemotherapy group were 11% (3/26) and 3% (2/64), respectively; the PCR ratio of targeted group was 0/13; the PCR ratio of adenocarcinomain immune combined chemotherapy group and squamous cell carcinomain immune combined chemotherapy group were 0/4 and 1/6, respectively. Conclusions: Different neoadjuvant therapy may cause various histopathological changes in non-small cell lung cancer: more necrosis is noted in the chemotherapy group and regression bed frequently appears in the immune combined chemotherapy group. In the immune combined chemotherapy group, there are significant lymphoplasmacytic infiltration and lymphoid follicle formation in the lung parenchyma beside the tumor bed.
Collapse
|
136
|
Wang D, Li T, Xu Y, Yang X, He M, Zhang Z, Wu W, Yan Y. [Platelet-rich plasma alleviates myocardial ischemia-reperfusion injury in rats]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2021; 41:775-782. [PMID: 34134967 DOI: 10.12122/j.issn.1673-4254.2021.05.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the protective effect of platelet-rich plasma (PRP) against acute myocardial ischemiareperfusion (IR) injury and the possible mechanism. OBJECTIVE Aortic blood samples were collected from 10 SD rats to prepare PRP, in which the concentrations of platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor-β1 (TGF-β1) were measured. Cell models of IR injury were established in primary cultures of neonatal SD rat cardiomyocytes by exposing the cells to 3 h of hypoxia. The cells were then reoxygenated and co-cultured with 1%, 5%, 10%, and 20% volume of PRP for 12 h, and the changes in cell viability was assessed. Immunofluorescence staining of the cardiomyocytes was performed, and the cellular expression of AMPK and its phosphorylation level were detected. The effects of PRP on the proliferation and migration of rat aortic endothelial cells (RAOECs) were examined. In a SD rat model of myocardial IR injury, 100 μL of PRP (n= 20) or normal saline (n=20) was injected at 4 sites around the ligation site immediately after cardiac reperfusion. One day after the injection, 6 rats were selected from each group for TTC staining of the myocardial tissues and measurement of troponin Ⅰ content. One week later, the cardiac function of the remaining rats was assessed by echocardiography, and HE staining of the myocardial tissues was performed. The effect of PRP treatment for 24 h on polarization of M1 and M2 macrophages was also examined by flow cytometry in RAW264.7 cells after hypoxic exposure for 3 h. OBJECTIVE The concentrations of PDGF-BB and TGF-β1 were significantly higher in PRP than in whole blood. Addition of 1% volume of PRP significantly reduced death of the cardiomyocytes following reoxygenation, and this effect was closely related with the activation of AMPK. Treatment with PRP obviously promoted the proliferation and migration of RAOECs. In rat models of acute myocardial IR injury, injections of PRP significantly reduced the infarct size and troponin Ⅰ concentration as compared with saline injection (P < 0.001). One week after PRP injection, the rats showed significantly improved cardiac function with a lowered level of inflammatory response in comparison with the rats with saline injection. In RAW264.7 cells with hypoxic exposure, treatment with PRP obviously decreased the number of M1 macrophages and increase the number of M2 macrophages. OBJECTIVE PRP can improve acute myocardial IR injury in rats by phosphorylating AMPK and regulating macrophage polarization, which produces a protective immunomodulatory effect on the ischemic myocardial tissues.
Collapse
|
137
|
Li C, Liu Z, Zhou J, Meng X, Liu S, Li W, Zhang X, Zhou J, Yao W, Dong C, Cao Y, Li R, Chen B, Jiang A, Jiang Y, Ning C, Zhao F, Wei Y, Sun SC, Tao J, Wu W, Shen M, Liu H. Insulin-like growth factor-I prevents hypoxia-inducible factor-1 alpha-dependent G1/S arrest by activating cyclin E/cyclin-dependent kinase2 via the phoshatidylinositol-3 kinase/AKT/forkhead box O1/Cdkn1b pathway in porcine granulosa cells†. Biol Reprod 2021; 102:116-132. [PMID: 31435642 DOI: 10.1093/biolre/ioz162] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 05/23/2019] [Accepted: 08/12/2019] [Indexed: 11/13/2022] Open
Abstract
As the follicle develops, the thickening of the granulosa compartment leads to progressively deficient supply of oxygen in granulosa cells (GCs) due to the growing distances from the follicular vessels. These conditions are believed to cause hypoxia in GCs during folliculogenesis. Upon hypoxic conditions, several types of mammalian cells have been reported to undergo cell cycle arrest. However, it remains unclear whether hypoxia exerts any impact on cell cycle progression of GCs. On the other hand, although the GCs may live in a hypoxic environment, their mitotic capability appears to be unaffected in growing follicles. It thus raises the question whether there are certain intraovarian factors that might overcome the inhibitory effects of hypoxia. The present study provides the first evidence suggesting that cobalt chloride (CoCl2)-mimicked hypoxia prevented G1-to-S cell cycle progression in porcine GCs. In addition, we demonstrated that the inhibitory effects of CoCl2 on GCs cell cycle are mediated through hypoxia-inducible factor-1 alpha/FOXO1/Cdkn1b pathway. Moreover, we identified insulin-like growth factor-I (IGF-I) as an intrafollicular factor required for cell cycle recovery by binding to IGF-I receptor in GCs suffering CoCl2 stimulation. Further investigations confirmed a role of IGF-I in preserving G1/S progression of CoCl2-treated GCs via activating the cyclin E/cyclin-dependent kinase2 complex through the phoshatidylinositol-3 kinase/protein kinase B (AKT)/FOXO1/Cdkn1b axis. Although the present findings were based on a hypoxia mimicking model by using CoCl2, our study might shed new light on the regulatory mechanism of GCs cell cycle upon hypoxic stimulation.
Collapse
|
138
|
Zhao QN, Wu W, Li CG, Bai Y, Zhu BL. [Plasma differentially expressed genes and bioinformatics analysis of workers occupationally exposed to mercury]. ZHONGHUA LAO DONG WEI SHENG ZHI YE BING ZA ZHI = ZHONGHUA LAODONG WEISHENG ZHIYEBING ZAZHI = CHINESE JOURNAL OF INDUSTRIAL HYGIENE AND OCCUPATIONAL DISEASES 2021; 39:337-342. [PMID: 34074076 DOI: 10.3760/cma.j.cn121094-20200106-00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To screen and identify plasma differentially expressed genes and related signal pathway by human gene expression profile array and fluorescent quantitative PCR. Methods: From September 2018 to October 2019, 291 workers from a Mercury-in-glass thermometer factory in Jiangsu Province were selected for an occupational health examination, a total of 60 persons were divided into two groups: high and low mercury exposure groups (30 persons in each group) . Plasma total RNA samples from the high exposure group and the low exposure group (10 cases each) were detected by gene expression microarray, and differentially expressed genes (DEGs) with fold change >2 were selected. DEGs were submitted to David and Metascape for gene function clustering, pathway and protein interaction network analysis. Finally, fluorescence quantitative PCR was performed to verify the changes in the expression levels of key DEGs in the high exposure group and the low exposure group (another 20 cases in each group) . Results: A total of 269 DEGs, of which 203 up regulated and 66 down regulated were identified in the differential expression analysis of gene expression microarray. Bioinformatics analysis suggested that, DEGs were involved in forebrain development, glial cell fate determinants of GO biological process and PID NF-KB, PTEN signal pathway. NFE2L1, SOX8, SOX6 and RNF2 (P<0.05) were confirmed down regulated in high level group by fluorescent quantitative PCR compared with the low level group (fold changes were 2.10, 11.52, 2.19, and 4.38 respectively) . Conclusion: The plasma NFE2L1, SOX8, SOX6 and RNF2 gene expressions are significantly altered in occupa tional high mercury exposure population. PTEN signaling pathway and fate of glia cells determines the biological process may be closely related to the body injury caused by mercury exposure.
Collapse
|
139
|
Du CQ, Wei H, Zhang C, Zhang M, Hu MH, Hou L, Wu W, Liang Y, Luo XP. [The application of continuous glucose monitoring in the management of hepatic glycogen storage disease]. ZHONGHUA ER KE ZA ZHI = CHINESE JOURNAL OF PEDIATRICS 2021; 59:452-458. [PMID: 34102817 DOI: 10.3760/cma.j.cn112140-20210321-00235] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Objective: Continuous glucose monitoring (CGM) were performed in children with hepatic glycogen storage disease (GSD) to accurately understand the situation of glucose levels during their treatment, and to provide support for optimizing their nutritional management. Methods: In this retrospective research, 42 patients with hepatic GSD who under went 72 h CGM were collected from Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology from October 2019 to January 2020. According to the genetic test results, they were divided into 5 groups: type Ⅰa, type Ⅰb, type Ⅲa, type Ⅵ and type Ⅸa. After long-term follow up and regular treatment, the clinical data (induding course, age, height, weight and biochemical parameters, etc.) on the day of CGM were summarized, and 72 h CGM were performed to assess the occurrence of hypoglycemia and hyperglycemia.χ² test, Fisher exact probability method, t test, analysis of variance or nonparametric test were used for comparison between groups. Results: Forty-two cases of hepatic GSD patients included 25 males and 17 females (20 cases of type Ⅰa, 3 cases of type Ⅰb, 10 cases of type Ⅲa, 3 cases of type Ⅵ and 6 cases of type Ⅸa).The age was 9.5 (6.7, 12.9) years, and the course of disease was 6.8 (5.1, 11.3) years. The average levels of glucose of the patients were all normal. However, the levels of standard deviation of blood glucose (SDBG) and mean amplitude of glycemic excursion (MAGE) were significantly different (F=2.747, 3.029,both P<0.05). Among them, the SDBG of type Ⅰa and Ⅲa were significantly higher than those of type Ⅸa ((1.10±0.36), (0.98±0.30) vs. (0.62±0.26) mmol/L, t=3.010, 2.440, both P<0.05), while the MAGE of type Ⅰ was higher than that of Ⅸa and Ⅲa ((2.3±0.9) mmol/L vs. (1.2±0.6) and (1.7±0.6) mmol/L, t=2.734, 2.302, both P<0.05, respectively). Conclusions: CGMS can accurately assess the fluctuations of blood glucose and effectively detect hidden hypoglycemia and hyperglycemia in hepatic GSD patients. For different types of hepatic GSD, individualized corn starch treatment doses should be given according to the different situation of blood glucose, so as to optimize the patient's treatment and improve their prognosis.
Collapse
|
140
|
Liu XY, Zhou WY, Wu W, He MR, Zheng DK, Ji GY, Ma WJ, Chen Y. [Serological screening and analysis of clinical characteristics for celiac disease in susceptible population in Southern China]. ZHONGHUA NEI KE ZA ZHI 2021; 60:539-543. [PMID: 34058810 DOI: 10.3760/cma.j.cn112138-20200715-00671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To determine the seroprevalence of celiac disease in susceptible population, and to analyze the relationship between demographic characteristics, dietary habits, lifestyle and serological positivity so as to provide guidance for the prevention and treatment of celiac disease in Southern China. Methods: A total of 1 273 individuals who participated in Guangdong Province Health Screening Program in 2015, were selected as serologically positive subjects of celiac disease, including people with irritable bowel syndrome, colitis, diarrhea, anemia, low BMI, short stature, type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), ankylosing spondylitis, psoriasis and bristol grade=6 or 7. All subjects were tested for serum IgA anti-tissue transglutaminase antibodies (TTGA), IgA antibodies against deamidated gliadin peptides(DGPA) and IgG against deamidated gliadin peptides (DGPG). Dietary habits, lifestyle and demographic characteristics were compared in subgroups. Results: The seroprevalence of celiac disease in susceptible population was 0.94% (95%CI 0.54%-1.64%) including 0.08% (1/1 273) for TTGA, 0.47% (6/1 273) for DGPA, and 0.39% (5/1 273) for DGPG. The seropositive rate was 3.6% (1/28) in patients with psoriasis, 2.1% (2/95) in the low BMI group, 1.9% (1/53) in T1DM group, 1.8% (3/169) in diarrhea group and 1.1% (5/463) in RA group. No significant difference was found in age, gender, high carbohydrate diet or lifestyle between the negative and the positive subjects. Conclusions: In Southern China, the seropositive rate of celiac disease is 0.94% in susceptible population, which prompts an urgent need of serological screening for early diagnosis.
Collapse
|
141
|
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Silva MG, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez‐Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Sabattini E, Salles G, Santambrogio E, Scarfó L, Stathis A, Stüssi G, Geyer JT, Tapia G, Thieblemont C, Tousseyn T, Tucci A, Visco C, Vitolo U, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, Leval L, Dirnhofer S, Pileri SA, Piris MÁ, Traverse‐Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.43_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
142
|
Terzi di Bergamo L, Forestieri G, Loh JW, Singh A, Spina V, Zucchetto A, Condoluci A, Faderl M, Koch R, Bruscaggin A, Pini K, Wu W, Piffaretti D, Bittolo T, Tissino E, Paoli L, Deambrogi C, Frustaci AM, Autore F, Merli M, Scarfò L, Rasi S, Passweg J, Moia R, Martines C, Ghia P, Cavalli F, Zucca E, Gerber B, Gillessen S, Stüssi G, Montillo M, Passamonti F, Gregor M, Laurenti L, Tedeschi A, Gaidano G, Efremov D, Gattei V, Khiabanian H, Rossi D. ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAY. Hematol Oncol 2021. [DOI: 10.1002/hon.29_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
143
|
Martin-Gutierrez L, Peng J, Robinson G, Naja M, Peckham H, Wu W, Isenberg D, Jury E, Ciurtin C. POS0174 IMMUNOPHENOTYPE OF SJÖGREN´S SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IDENTIFIED TWO ENDOTYPES WITH POTENTIAL THERAPEUTIC IMPLICATIONS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Primary Sjögren’s syndrome (pSS) and systemic lupus erythematosus (SLE) are chronic autoimmune rheumatic diseases (ARDs) that share a strong female gender bias, as well as genetic, clinical and serological characteristics.Although significant progress has been made in improving treatment and patient related outcomes in pSS and SLE, there is a need for improved early diagnosis, adequate therapy monitoring, treatment of refractory manifestations and strategies to address co-morbidities.However, the results of many clinical trials are disappointing, and nobiologic treatments are licensedin pSS, while few are available for SLE patients with refractory disease.Objectives:Identifying shared immunological features between patients with pSS and SLE that could lead to better treatment selection using a stratification approach.Methods:Immune-phenotyping of 29 immune-cell subsets in peripheral blood from patients with pSS (n=45), SLE (n=29) and secondary SS associated with SLE (SLE/SS) (n=14) with low disease activity or in clinical remission, and sex-matched healthy controls (n=31), was performed using flow cytometry. Data were analysed using logistic regression and multiple t-tests andsupervised machine learning (balanced random forest-BRF, sparse partial least squares discriminant analysis-sPLS-DA). Patients were stratified by k-means clustering. Clinical trajectories were analysed over 5 year follow-up.Results:Comparing the immune profile of pSS and SLE patients using a variety of statistical and machine learning (ML) approaches, identified very few statistically significant differences between the two cohorts despite patients having a different clinical presentation and diagnosis. Thus, we hypothesised that immune-based subtypes could be shared between pSS, SLE and SLE/SS patients. Unsupervised k-means clustering was applied to the immunological features of the combined patient cohorts and two distinct patient endotypes, were identified: Group-1 (n=49; pSS=24, SLE=19, SLE/SS=6) and Group-2 (n=39; pSS=21, SLE=10, SLE/SS=8). Significant differences in immune-cell phenotypes across B-cell and T-cell subsets were identified by logistic regression, BRF (AUC=0.9942, assessed by 10-fold cross-validation) and sPLS-DA analysis. Comparison of the multiple analysis approaches identified eight common immune-cell subsets, including total and memory CD4+ and CD8+ T-cell subsets but no B-cell subsets. Using this common immune-signature the stratification between the groups was maintained and slightly improved (AUC=0.9979 and accuracy 96.16%). Interestingly, patients in Group-2 had elevated disease activity measures at baseline and over a 5-year trajectory compared to Group-1. Finally, correlation analysis identifed correlations between disease activity markers and the top ranked immune features from the ML models.Conclusion:The identified immune-cell signatures could reflect the underlying disease pathogenesis that spans diagnositc criteria and could be used to select patients for targeted therapeutic approaches.Acknowledgements:LM-G is supported by a project grant from The Dunhill Medical Trust (RPGF1902\117); JP is supported by Versus Arthritis (21226). GAR is supported by Lupus UK, The Rosetrees Trust (M409) and Versus Arthritis (21593). MN is supported by NIHR UCLH Biomedical Research Centre (BRC525/III/CC/191350). HP has a Versus Arthritis PhD studentship (22203). This work was performed within the Centre for Adolescent Rheumatology Versus Arthritis at UCL UCLH and GOSH supported by grants from Versus Arthritis (21593 and 20164), GOSCC, and the NIHR-Biomedical Research Centres at both GOSH and UCLH.We would like to thank Mr Jamie Evans for expert support with flow cytometry analysis and Ms Eve McLoughlin for support with patient recruitment.Disclosure of Interests:None declared
Collapse
|
144
|
Zhu H, Sha Y, Wu W, Chen R, Yang Y, Qiu J, Mi H, Peng C, Ding C, Wang Z, Fan L, Xu W, Li J. ZANUBRUTINIB, LENALIDOMIDE PLUS R‐CHOP (ZR
2
‐CHOP) AS THE TREATMENT FOR DIFFUSED LARGE B‐CELL LYMPHOMA (DLBCL). Hematol Oncol 2021. [DOI: 10.1002/hon.49_2881] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
145
|
Abratenko P, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Balasubramanian S, Baller B, Barnes C, Barr G, Basque V, Bathe-Peters L, Benevides Rodrigues O, Berkman S, Bhanderi A, Bhat A, Bishai M, Blake A, Bolton T, Camilleri L, Caratelli D, Caro Terrazas I, Castillo Fernandez R, Cavanna F, Cerati G, Chen Y, Church E, Cianci D, Conrad J, Convery M, Cooper-Troendle L, Crespo-Anadón J, Del Tutto M, Devitt D, Diurba R, Domine L, Dorrill R, Duffy K, Dytman S, Eberly B, Ereditato A, Escudero Sanchez L, Evans J, Fiorentini Aguirre G, Fitzpatrick R, Fleming B, Foppiani N, Franco D, Furmanski A, Garcia-Gamez D, Gardiner S, Ge G, Gollapinni S, Goodwin O, Gramellini E, Green P, Greenlee H, Gu W, Guenette R, Guzowski P, Hall E, Hamilton P, Hen O, Horton-Smith G, Hourlier A, Huang EC, Itay R, James C, Jan de Vries J, Ji X, Jiang L, Jo J, Johnson R, Jwa YJ, Kamp N, Karagiorgi G, Ketchum W, Kirby B, Kirby M, Kobilarcik T, Kreslo I, LaZur R, Lepetic I, Li K, Li Y, Littlejohn B, Lorca D, Louis W, Luo X, Marchionni A, Marcocci S, Mariani C, Marsden D, Marshall J, Martin-Albo J, Martinez Caicedo D, Mason K, Mastbaum A, McConkey N, Meddage V, Mettler T, Miller K, Mills J, Mistry K, Mogan A, Mohayai T, Moon J, Mooney M, Moor A, Moore C, Mousseau J, Murphy M, Naples D, Navrer-Agasson A, Neely R, Nienaber P, Nowak J, Palamara O, Paolone V, Papadopoulou A, Papavassiliou V, Pate S, Paudel A, Pavlovic Z, Piasetzky E, Ponce-Pinto I, Porzio D, Prince S, Qian X, Raaf J, Radeka V, Rafique A, Reggiani-Guzzo M, Ren L, Rochester L, Rodriguez Rondon J, Rogers H, Rosenberg M, Ross-Lonergan M, Russell B, Scanavini G, Schmitz D, Schukraft A, Shaevitz M, Sharankova R, Sinclair J, Smith A, Snider E, Soderberg M, Söldner-Rembold S, Soleti S, Spentzouris P, Spitz J, Stancari M, John J, Strauss T, Sutton K, Sword-Fehlberg S, Szelc A, Tagg N, Tang W, Terao K, Thorpe C, Toups M, Tsai YT, Tufanli S, Uchida M, Usher T, Van De Pontseele W, Viren B, Weber M, Wei H, Williams Z, Wolbers S, Wongjirad T, Wospakrik M, Wu W, Yang T, Yarbrough G, Yates L, Zeller G, Zennamo J, Zhang C. Convolutional neural network for multiple particle identification in the MicroBooNE liquid argon time projection chamber. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.103.092003] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
146
|
Wu MN, Yang JL, Shen SJ, Wang L, Zheng WJ, Wu W, Yao M, Yao DF. [Expression of tuftelin protein and its clinical value in HBV-related liver cancer tissues]. ZHONGHUA GAN ZANG BING ZA ZHI = ZHONGHUA GANZANGBING ZAZHI = CHINESE JOURNAL OF HEPATOLOGY 2021; 29:338-343. [PMID: 33979960 DOI: 10.3760/cma.j.cn501113-20200918-00519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To analyze the expression of tuftelin protein (TUFT1) and its clinical value in hepatocellular carcinoma (HCC)-related liver cancer tissues. Methods: The biological information data of TUFT1 mRNA expression in liver cancer and non-cancer tissues were analyzed from the TCGA and Oncomine database. After the approval of the ethics committee, the self-pairing method was used to collect the postoperative cancer and para-carcinoma tissues of 132 HCC cases hospitalized between January 2009 and December 2014. Tissue microarray and immunohistochemistry (IHC) were used to analyze the expression of TUFT1 in liver tissues. According to IHC staining, liver cancer was divided into high TUFT1 and low/no expression group. Combined with clinical data, the clinicopathological characteristics were statistically analyzed between and within the groups. The 5-year overall survival (OS) and disease-free survival (DFS) was analyzed by correlation analysis. Results: IHC staining showed that TUFT1 in cancer tissue was localized in the cytoplasm and cell membrane, and its positive expression rate was significantly higher in the liver cancer group (87.1%) than the para-carcinoma group (64.4%) (χ (2) = 18.563, P < 0.001). TUFT1 expression intensity in patients with liver cancer was significantly correlated with HBeAg positive (χ (2) = 4.080, P = 0.043), tumor size (χ (2) = 9.388, P = 0.002), vascular invasion (χ (2) = 14.885, P < 0.001), TNM stage (χ (2) = 13.516, P < 0.001) and ascites (χ (2) = 5.940, P = 0.015). TUFT1 high expression was negatively correlated with OS and DFS (P < 0.001). Conclusion: The overexpression of TUFT1 is closely related to HBV replication, vascular invasion and poor prognosis, and it is expected to become a useful marker for liver cancer diagnosis and prognosis.
Collapse
|
147
|
Chen Y, Zhou J, Lee S, Liu T, Wu W, Hothi S, Zhang Q, Tse G, Wang Y. Electronic frailty index for predicting mortality outcome of patients undergoing transaortic valvular implantation. EUROPEAN HEART JOURNAL. ACUTE CARDIOVASCULAR CARE 2021. [DOI: 10.1093/ehjacc/zuab020.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Objective
Electronic frailty index for predicting mortality outcome of patients undergoing transaortic valvular implantation (TAVI) served as useful surrogates but is associated with a poor prognosis since it needs long time to determine the frailty status and develop the index based on electronic health records. We identify significant risk mortality predictors and tested the hypothesis that an electronic frailty index incorporating ECG measurements and laboratory examinations using a machine learning survival analysis approach can improve TAVI mortality prediction.
Design
A territory-wide observational study which involved a total of 450 patients (49.11% females, 22 mortalities) diagnosed undergoing TAVI and admitted to public hospitals from Hong Kong.
Methods
Demographics (TAVI presentation age, gender, severity of TR, AR, MR, PR, INR of TAVI presentation), prior comorbidities before TAVI presentation, ECG measurements, and CBC and LRFT laboratory examinations were analyzed. Cox regression and a supervised sequential ensemble learning algorithm: gradient boosting survival tree (GBST) model, was applied to predict mortality. Significant univariate and multivariate risk predictors of mortality were identified. Importance ranking of variables were obtained with GBST model and used to build the frailty models. Comparisons were provided with baseline models of random survival forests and multivariate Cox regression.
Results
The median TAVI presentation age was 82.3 years (83.8 years in mortalities, and 82.1 years in alive patients). INR of TAVI presentation in mortalities (median: 1.32) is much higher than alive ones (median: 1.07). Severe TR (hazard ratio, HR: 8.93, 95% CI: [3.22, 24.78], p value < 0.0001), INR of TAVI presentation (HR: 2.74, 95% CI: [1.84, 4.09], p value < 0.0001), cumulative hospital stays (HR: 1.01, 95% CI: [1.00, 1.01], p value = 0.0008), aspartate transaminase (HR: 1.01, 95% CI: [0.98, 1.002], p value = 0.0002), and bilirubin (HR: 1.02, 95% CI: [1.01, 1.02], p value = 0.0003) are significant mortality risk predictors. Machine learning survival analysis model found that APTT demonstrates the most important strength, followed by INR of TAVI presentation, severe TR status, cumulative hospital stays, cumulative readmission times, creatinine test, urate test ALP test, and ECG measurements of QTc and QT. GBST significantly outperformed random survival forests and multivariate Cox regression (precision: 0.91, recall: 0.89, AUC: 0.93, C-index: 0.96, and KS-index: 0.50) for mortality prediction.
Conclusions
Electronic frailty index based on demographics, prior comorbidities, hospitalization characteristics, ECG measurements, and laboratory examinations can efficiently predict mortality outcome of patients undergoing TAVI. Machine learning survival learning model significantly improves the risk prediction performance and improves the construction of the frailty models for tailored interventions of TAVI patients in clinical practices.
Collapse
|
148
|
Abi B, Acciarri R, Acero MA, Adamov G, Adams D, Adinolfi M, Ahmad Z, Ahmed J, Alion T, Monsalve SA, Alt C, Anderson J, Andreopoulos C, Andrews MP, Andrianala F, Andringa S, Ankowski A, Antonova M, Antusch S, Aranda-Fernandez A, Ariga A, Arnold LO, Arroyave MA, Asaadi J, Aurisano A, Aushev V, Autiero D, Azfar F, Back H, Back JJ, Backhouse C, Baesso P, Bagby L, Bajou R, Balasubramanian S, Baldi P, Bambah B, Barao F, Barenboim G, Barker GJ, Barkhouse W, Barnes C, Barr G, Monarca JB, Barros N, Barrow JL, Bashyal A, Basque V, Bay F, Alba JLB, Beacom JF, Bechetoille E, Behera B, Bellantoni L, Bellettini G, Bellini V, Beltramello O, Belver D, Benekos N, Neves FB, Berger J, Berkman S, Bernardini P, Berner RM, Berns H, Bertolucci S, Betancourt M, Bezawada Y, Bhattacharjee M, Bhuyan B, Biagi S, Bian J, Biassoni M, Biery K, Bilki B, Bishai M, Bitadze A, Blake A, Siffert BB, Blaszczyk FDM, Blazey GC, Blucher E, Boissevain J, Bolognesi S, Bolton T, Bonesini M, Bongrand M, Bonini F, Booth A, Booth C, Bordoni S, Borkum A, Boschi T, Bostan N, Bour P, Boyd SB, Boyden D, Bracinik J, Braga D, Brailsford D, Brandt A, Bremer J, Brew C, Brianne E, Brice SJ, Brizzolari C, Bromberg C, Brooijmans G, Brooke J, Bross A, Brunetti G, Buchanan N, Budd H, Caiulo D, Calafiura P, Calcutt J, Calin M, Calvez S, Calvo E, Camilleri L, Caminata A, Campanelli M, Caratelli D, Carini G, Carlus B, Carniti P, Terrazas IC, Carranza H, Castillo A, Castromonte C, Cattadori C, Cavalier F, Cavanna F, Centro S, Cerati G, Cervelli A, Villanueva AC, Chalifour M, Chang C, Chardonnet E, Chatterjee A, Chattopadhyay S, Chaves J, Chen H, Chen M, Chen Y, Cherdack D, Chi C, Childress S, Chiriacescu A, Cho K, Choubey S, Christensen A, Christian D, Christodoulou G, Church E, Clarke P, Coan TE, Cocco AG, Coelho JAB, Conley E, Conrad JM, Convery M, Corwin L, Cotte P, Cremaldi L, Cremonesi L, Crespo-Anadón JI, Cristaldo E, Cross R, Cuesta C, Cui Y, Cussans D, Dabrowski M, da Motta H, Peres LDS, David C, David Q, Davies GS, Davini S, Dawson J, De K, De Almeida RM, Debbins P, De Bonis I, Decowski MP, de Gouvêa A, De Holanda PC, De Icaza Astiz IL, Deisting A, De Jong P, Delbart A, Delepine D, Delgado M, Dell’Acqua A, De Lurgio P, de Mello Neto JRT, DeMuth DM, Dennis S, Densham C, Deptuch G, De Roeck A, De Romeri V, De Vries JJ, Dharmapalan R, Dias M, Diaz F, Díaz JS, Di Domizio S, Di Giulio L, Ding P, Di Noto L, Distefano C, Diurba R, Diwan M, Djurcic Z, Dokania N, Dolinski MJ, Domine L, Douglas D, Drielsma F, Duchesneau D, Duffy K, Dunne P, Durkin T, Duyang H, Dvornikov O, Dwyer DA, Dyshkant AS, Eads M, Edmunds D, Eisch J, Emery S, Ereditato A, Escobar CO, Sanchez LE, Evans JJ, Ewart E, Ezeribe AC, Fahey K, Falcone A, Farnese C, Farzan Y, Felix J, Fernandez-Martinez E, Fernandez Menendez P, Ferraro F, Fields L, Filkins A, Filthaut F, Fitzpatrick RS, Flanagan W, Fleming B, Flight R, Fowler J, Fox W, Franc J, Francis K, Franco D, Freeman J, Freestone J, Fried J, Friedland A, Fuess S, Furic I, Furmanski AP, Gago A, Gallagher H, Gallego-Ros A, Gallice N, Galymov V, Gamberini E, Gamble T, Gandhi R, Gandrajula R, Gao S, Garcia-Gamez D, García-Peris MÁ, Gardiner S, Gastler D, Ge G, Gelli B, Gendotti A, Gent S, Ghorbani-Moghaddam Z, Gibin D, Gil-Botella I, Girerd C, Giri AK, Gnani D, Gogota O, Gold M, Gollapinni S, Gollwitzer K, Gomes RA, Bermeo LVG, Fajardo LSG, Gonnella F, Gonzalez-Cuevas JA, Goodman MC, Goodwin O, Goswami S, Gotti C, Goudzovski E, Grace C, Graham M, Gramellini E, Gran R, Granados E, Grant A, Grant C, Gratieri D, Green P, Green S, Greenler L, Greenwood M, Greer J, Griffith WC, Groh M, Grudzinski J, Grzelak K, Gu W, Guarino V, Guenette R, Guglielmi A, Guo B, Guthikonda KK, Gutierrez R, Guzowski P, Guzzo MM, Gwon S, Habig A, Hackenburg A, Hadavand H, Haenni R, Hahn A, Haigh J, Haiston J, Hamernik T, Hamilton P, Han J, Harder K, Harris DA, Hartnell J, Hasegawa T, Hatcher R, Hazen E, Heavey A, Heeger KM, Heise J, Hennessy K, Henry S, Morquecho MAH, Herner K, Hertel L, Hesam AS, Hewes J, Higuera A, Hill T, Hillier SJ, Himmel A, Hoff J, Hohl C, Holin A, Hoppe E, Horton-Smith GA, Hostert M, Hourlier A, Howard B, Howell R, Huang J, Huang J, Hugon J, Iles G, Ilic N, Iliescu AM, Illingworth R, Ioannisian A, Itay R, Izmaylov A, James E, Jargowsky B, Jediny F, Jesùs-Valls C, Ji X, Jiang L, Jiménez S, Jipa A, Joglekar A, Johnson C, Johnson R, Jones B, Jones S, Jung CK, Junk T, Jwa Y, Kabirnezhad M, Kaboth A, Kadenko I, Kamiya F, Karagiorgi G, Karcher A, Karolak M, Karyotakis Y, Kasai S, Kasetti SP, Kashur L, Kazaryan N, Kearns E, Keener P, Kelly KJ, Kemp E, Ketchum W, Kettell SH, Khabibullin M, Khotjantsev A, Khvedelidze A, Kim D, King B, Kirby B, Kirby M, Klein J, Koehler K, Koerner LW, Kohn S, Koller PP, Kordosky M, Kosc T, Kose U, Kostelecký VA, Kothekar K, Krennrich F, Kreslo I, Kudenko Y, Kudryavtsev VA, Kulagin S, Kumar J, Kumar R, Kuruppu C, Kus V, Kutter T, Lambert A, Lande K, Lane CE, Lang K, Langford T, Lasorak P, Last D, Lastoria C, Laundrie A, Lawrence A, Lazanu I, LaZur R, Le T, Learned J, LeBrun P, Miotto GL, Lehnert R, de Oliveira MAL, Leitner M, Leyton M, Li L, Li S, Li SW, Li T, Li Y, Liao H, Lin CS, Lin S, Lister A, Littlejohn BR, Liu J, Lockwitz S, Loew T, Lokajicek M, Lomidze I, Long K, Loo K, Lorca D, Lord T, LoSecco JM, Louis WC, Luk KB, Luo X, Lurkin N, Lux T, Luzio VP, MacFarland D, Machado AA, Machado P, Macias CT, Macier JR, Maddalena A, Madigan P, Magill S, Mahn K, Maio A, Maloney JA, Mandrioli G, Maneira J, Manenti L, Manly S, Mann A, Manolopoulos K, Plata MM, Marchionni A, Marciano W, Marfatia D, Mariani C, Maricic J, Marinho F, Marino AD, Marshak M, Marshall C, Marshall J, Marteau J, Martin-Albo J, Martinez N, Caicedo DAM, Martynenko S, Mason K, Mastbaum A, Masud M, Matsuno S, Matthews J, Mauger C, Mauri N, Mavrokoridis K, Mazza R, Mazzacane A, Mazzucato E, McCluskey E, McConkey N, McFarland KS, McGrew C, McNab A, Mefodiev A, Mehta P, Melas P, Mellinato M, Mena O, Menary S, Mendez H, Menegolli A, Meng G, Messier MD, Metcalf W, Mewes M, Meyer H, Miao T, Michna G, Miedema T, Migenda J, Milincic R, Miller W, Mills J, Milne C, Mineev O, Miranda OG, Miryala S, Mishra CS, Mishra SR, Mislivec A, Mladenov D, Mocioiu I, Moffat K, Moggi N, Mohanta R, Mohayai TA, Mokhov N, Molina J, Bueno LM, Montanari A, Montanari C, Montanari D, Zetina LMM, Moon J, Mooney M, Moor A, Moreno D, Morgan B, Morris C, Mossey C, Motuk E, Moura CA, Mousseau J, Mu W, Mualem L, Mueller J, Muether M, Mufson S, Muheim F, Muir A, Mulhearn M, Muramatsu H, Murphy S, Musser J, Nachtman J, Nagu S, Nalbandyan M, Nandakumar R, Naples D, Narita S, Navas-Nicolás D, Nayak N, Nebot-Guinot M, Necib L, Negishi K, Nelson JK, Nesbit J, Nessi M, Newbold D, Newcomer M, Newhart D, Nichol R, Niner E, Nishimura K, Norman A, Norrick A, Northrop R, Novella P, Nowak JA, Oberling M, Del Campo AO, Olivier A, Onel Y, Onishchuk Y, Ott J, Pagani L, Pakvasa S, Palamara O, Palestini S, Paley JM, Pallavicini M, Palomares C, Pantic E, Paolone V, Papadimitriou V, Papaleo R, Papanestis A, Paramesvaran S, Park JC, Parke S, Parsa Z, Parvu M, Pascoli S, Pasqualini L, Pasternak J, Pater J, Patrick C, Patrizii L, Patterson RB, Patton SJ, Patzak T, Paudel A, Paulos B, Paulucci L, Pavlovic Z, Pawloski G, Payne D, Pec V, Peeters SJM, Penichot Y, Pennacchio E, Penzo A, Peres OLG, Perry J, Pershey D, Pessina G, Petrillo G, Petta C, Petti R, Piastra F, Pickering L, Pietropaolo F, Pillow J, Pinzino J, Plunkett R, Poling R, Pons X, Poonthottathil N, Pordes S, Potekhin M, Potenza R, Potukuchi BVKS, Pozimski J, Pozzato M, Prakash S, Prakash T, Prince S, Prior G, Pugnere D, Qi K, Qian X, Raaf JL, Raboanary R, Radeka V, Rademacker J, Radics B, Rafique A, Raguzin E, Rai M, Rajaoalisoa M, Rakhno I, Rakotondramanana HT, Rakotondravohitra L, Ramachers YA, Rameika R, Delgado MAR, Ramson B, Rappoldi A, Raselli G, Ratoff P, Ravat S, Razafinime H, Real JS, Rebel B, Redondo D, Reggiani-Guzzo M, Rehak T, Reichenbacher J, Reitzner SD, Renshaw A, Rescia S, Resnati F, Reynolds A, Riccobene G, Rice LCJ, Rielage K, Rigaut Y, Rivera D, Rochester L, Roda M, Rodrigues P, Alonso MJR, Rondon JR, Roeth AJ, Rogers H, Rosauro-Alcaraz S, Rossella M, Rout J, Roy S, Rubbia A, Rubbia C, Russell B, Russell J, Ruterbories D, Saakyan R, Sacerdoti S, Safford T, Sahu N, Sala P, Samios N, Sanchez MC, Sanders DA, Sankey D, Santana S, Santos-Maldonado M, Saoulidou N, Sapienza P, Sarasty C, Sarcevic I, Savage G, Savinov V, Scaramelli A, Scarff A, Scarpelli A, Schaffer T, Schellman H, Schlabach P, Schmitz D, Scholberg K, Schukraft A, Segreto E, Sensenig J, Seong I, Sergi A, Sergiampietri F, Sgalaberna D, Shaevitz MH, Shafaq S, Shamma M, Sharma HR, Sharma R, Shaw T, Shepherd-Themistocleous C, Shin S, Shooltz D, Shrock R, Simard L, Simos N, Sinclair J, Sinev G, Singh J, Singh J, Singh V, Sipos R, Sippach FW, Sirri G, Sitraka A, Siyeon K, Smargianaki D, Smith A, Smith A, Smith E, Smith P, Smolik J, Smy M, Snopok P, Nunes MS, Sobel H, Soderberg M, Salinas CJS, Söldner-Rembold S, Solomey N, Solovov V, Sondheim WE, Sorel M, Soto-Oton J, Sousa A, Soustruznik K, Spagliardi F, Spanu M, Spitz J, Spooner NJC, Spurgeon K, Staley R, Stancari M, Stanco L, Steiner HM, Stewart J, Stillwell B, Stock J, Stocker F, Stocks D, Stokes T, Strait M, Strauss T, Striganov S, Stuart A, Summers D, Surdo A, Susic V, Suter L, Sutera CM, Svoboda R, Szczerbinska B, Szelc AM, Talaga R, Tanaka HA, Oregui BT, Tapper A, Tariq S, Tatar E, Tayloe R, Teklu AM, Tenti M, Terao K, Ternes CA, Terranova F, Testera G, Thea A, Thompson JL, Thorn C, Timm SC, Todd J, Tonazzo A, Torti M, Tortola M, Tortorici F, Totani D, Toups M, Touramanis C, Trevor J, Trzaska WH, Tsai YT, Tsamalaidze Z, Tsang KV, Tsverava N, Tufanli S, Tull C, Tyley E, Tzanov M, Uchida MA, Urheim J, Usher T, Vagins MR, Vahle P, Valdiviesso GA, Valencia E, Vallari Z, Valle JWF, Vallecorsa S, Berg RV, de Water RGV, Forero DV, Varanini F, Vargas D, Varner G, Vasel J, Vasseur G, Vaziri K, Ventura S, Verdugo A, Vergani S, Vermeulen MA, Verzocchi M, de Souza HV, Vignoli C, Vilela C, Viren B, Vrba T, Wachala T, Waldron AV, Wallbank M, Wang H, Wang J, Wang Y, Wang Y, Warburton K, Warner D, Wascko M, Waters D, Watson A, Weatherly P, Weber A, Weber M, Wei H, Weinstein A, Wenman D, Wetstein M, While MR, White A, Whitehead LH, Whittington D, Wilking MJ, Wilkinson C, Williams Z, Wilson F, Wilson RJ, Wolcott J, Wongjirad T, Wood K, Wood L, Worcester E, Worcester M, Wret C, Wu W, Wu W, Xiao Y, Yang G, Yang T, Yershov N, Yonehara K, Young T, Yu B, Yu J, Zaki R, Zalesak J, Zambelli L, Zamorano B, Zani A, Zazueta L, Zeller GP, Zennamo J, Zeug K, Zhang C, Zhao M, Zhao Y, Zhivun E, Zhu G, Zimmerman ED, Zito M, Zucchelli S, Zuklin J, Zutshi V, Zwaska R. Prospects for beyond the Standard Model physics searches at the Deep Underground Neutrino Experiment: DUNE Collaboration. THE EUROPEAN PHYSICAL JOURNAL. C, PARTICLES AND FIELDS 2021; 81:322. [PMID: 34720713 PMCID: PMC8550327 DOI: 10.1140/epjc/s10052-021-09007-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 02/23/2021] [Indexed: 06/13/2023]
Abstract
The Deep Underground Neutrino Experiment (DUNE) will be a powerful tool for a variety of physics topics. The high-intensity proton beams provide a large neutrino flux, sampled by a near detector system consisting of a combination of capable precision detectors, and by the massive far detector system located deep underground. This configuration sets up DUNE as a machine for discovery, as it enables opportunities not only to perform precision neutrino measurements that may uncover deviations from the present three-flavor mixing paradigm, but also to discover new particles and unveil new interactions and symmetries beyond those predicted in the Standard Model (SM). Of the many potential beyond the Standard Model (BSM) topics DUNE will probe, this paper presents a selection of studies quantifying DUNE's sensitivities to sterile neutrino mixing, heavy neutral leptons, non-standard interactions, CPT symmetry violation, Lorentz invariance violation, neutrino trident production, dark matter from both beam induced and cosmogenic sources, baryon number violation, and other new physics topics that complement those at high-energy colliders and significantly extend the present reach.
Collapse
Grants
- MR/T019530/1 Medical Research Council
- MR/T041323/1 Medical Research Council
- MSMT, Czech Republic
- NRF, South Korea
- Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- SERI, Switzerland
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- U.S. Department of Energy
- CERN
- Türkiye Bilimsel ve Teknolojik Arastirma Kurumu
- The Royal Society, United Kingdom
- Canada Foundation for Innovation
- U.S. NSF
- FCT, Portugal
- CEA, France
- CNRS/IN2P3, France
- European Regional Development Fund
- Science and Technology Facilities Council
- H2020-EU, European Union
- IPP, Canada
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- CAM, Spain
- MSCA, European Union
- Instituto Nazionale di Fisica Nucleare
- Fundacção de Amparo à Pesquisa do Estado de Goiás
- Ministerio de Ciencia e Innovación
- Fundacion “La Caixa” Spain
Collapse
|
149
|
Jiang A, Yin D, Zhang L, Li B, Li R, Zhang X, Zhang Z, Liu H, Kim K, Wu W. Parsing the microRNA genetics basis regulating skeletal muscle fiber types and meat quality traits in pigs. Anim Genet 2021; 52:292-303. [PMID: 33840112 DOI: 10.1111/age.13064] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/23/2021] [Indexed: 12/29/2022]
Abstract
Muscle fibers are closely related to human diseases and livestock meat quality. However, the genetics basis of microRNAs (miRNAs) in regulating muscle fibers is not completely understood. In this study, we constructed the whole genome-wide miRNA expression profiles of porcine fast-twitch muscle [biceps femoris (Bf)] and slow-twitch muscle [soleus (Sol)], and identified hundreds of miRNAs, including four skeletal muscle-highly expressed miRNAs, ssc-miR-378, ssc-let-7f, ssc-miR-26a, and ssc-miR-27b-3p. Moreover, we identified 63 differentially expressed (DE) miRNAs between biceps femoris vs. soleus, which are the key candidate miRNAs regulating the skeletal muscle fiber types. In addition, we found that the expression of DE ssc-miR-499-5p was significantly correlated to the expression of Myoglobin (r = 0.6872, P < 0.0001) and Myosin heavy chain 7 (MYH7; r = 0.5408, P = 0.0020), and pH45 min (r = 0.3806, P = 0.0380) and glucose content (r = -0.4382, P = 0.0154); while the expression of DE ssc-miR-499-3p was significantly correlated to the expression of Myoglobin (r = 0.5340, P = 0.0024) and pH45 min (r = 0.4857, P = 0.0065). Taken together, our data established a sound foundation for further studies on the regulatory mechanisms of miRNAs in skeletal muscle fiber conversion and meat quality traits in livestock, and could provide a genetic explanation of the role of miRNAs in human muscular diseases.
Collapse
|
150
|
Du JB, Tao SY, Lin Y, Zhao Y, Lyu G, Xia YK, Lu CC, Wu W, Ma HX, Jin GF, Hu ZB, Shen HB. [Application of cloud-based information platform in China National Birth Cohort]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2021; 42:586-590. [PMID: 34814434 DOI: 10.3760/cma.j.cn112338-20201211-01404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Birth cohort is an important observational study which can continuously and dynamically collect the exposure changes and health outcomes from gametophyte development to adolescence and even old age. However, because of its complex design and difficult implementation, how to construct birth cohort with high quality and high efficiency is the main difficulty faced by epidemiologists at home and abroad. In 2016, China National Birth Cohort was officially launched. The network and information technology were used to explore, and a set of "cloud-based information platform" was established to support this queue construction, containing 16 units in China. After four years of development, the platform has formed a complete set of programs about the construction of cohort information platform, which including recruitment and follow-up management of participants, real-time data interaction, queue quality control, multi-level authority management and function division. The relevant design framework and functional elements provide the references to the future information construction of large-scale birth cohort and even population-based research in China.
Collapse
|